Document is current
Any future updates will be listed below
-
Authors
Wu, Yuqin https://orcid.org/0000-0002-1762-1896
Foollee, Ashish
Chan, Andrea Y.
Hille, Susanne https://orcid.org/0000-0002-9809-4636
Hauke, Jana
Challis, Matthew P.
Johnson, Jared L. https://orcid.org/0000-0003-1802-6527
Yaron, Tomer M.
Mynard, Victoria
Aung, Okka H.
Cleofe, Maria Almira S.
Huang, Cheng https://orcid.org/0000-0002-4575-1233
Lim Kam Sian, Terry C. C. https://orcid.org/0000-0001-7038-1214
Rahbari, Mohammad https://orcid.org/0000-0003-1133-2134
Gallage, Suchira https://orcid.org/0000-0002-1956-3597
Heikenwalder, Mathias https://orcid.org/0000-0002-3135-2274
Cantley, Lewis C. https://orcid.org/0000-0002-1298-7653
Schittenhelm, Ralf B. https://orcid.org/0000-0001-8738-1878
Formosa, Luke E. https://orcid.org/0000-0002-7740-6151
Smith, Greg C.
Okun, Jürgen G.
Müller, Oliver J. https://orcid.org/0000-0001-8223-2638
Rusu, Patricia M. https://orcid.org/0000-0001-7210-1976
Rose, Adam J. https://orcid.org/0000-0001-9132-8244
-
Funding
Funding for this research was provided by:
The Endocrine Society of Australia
Diabetes Australia Research Trust (Y22G)
- License Information
-
More Information
Article History
Received: 17 January 2024
Accepted: 16 September 2024
First Online: 27 September 2024
Competing interests
: A.J.R and P.M.R receive research support from Boehringer-Ingelheim, a pharmaceutical company, for an unrelated research project. L.C.C is a founder and member of the board of directors of Agios Pharmaceuticals and is a founder and receives research support from Petra Pharmaceuticals; is listed as an inventor on a patent (WO2019232403A1, Weill Cornell Medicine) for combination therapy for PI3K-associated disease or disorder, and the identification of therapeutic interventions to improve response to PI3K inhibitors for cancer treatment; is a co-founder and shareholder in Faeth Therapeutics; has equity in and consults for Cell Signaling Technologies, Volastra, Larkspur, Omega Funds and 1 Base Pharmaceuticals; and consults for Loxo-Lilly. T.M.Y. is a co-founder of DeStroke. J.L.J has received consulting fees from Scorpion Therapeutics and Volastra Therapeutics. All other authors declare no conflicts of interest.
